Providing solutions for professionals working in reproductive medicine
Board Certified and Full Professor of Obstetrics and Gynecology at the University of Valencia; Adjunct Clinical Professor, Department of Ob/Gyn, Stanford University School of Medicine, CA; Scientific Director of IGENOMIX.
Since 1991, his basic and clinical research has contributed to the advance of Reproductive Medicine, specifically in the understanding of human endometrial receptivity, embryo viability, embryonic implantation and endometriosis. He discovered the relevance of the interleukin-1 system in embryonic implantation (Simon et al., JCEM 1993; 1994; Endocrinology 1994; BOR 2006). He demonstrated the deleterious effect of high hormonal levels in patients with high response to gonadotrophins thus modifying the established clinical practice (HR1995; Fertil Steril 1996; 1998). He pioneered the concept that human oocytes are affected in endometriosis (HR 1994; Fertil Steril 2000) thus changing the clinical practice in oocyte donation. He proposed a new embryo coculture system, now successfully used worldwide (JCEM 1996; Fertil Steril 2003). His basic research on endometrial receptivity led him to create and patent a customized array named endometrial receptivity array (ERA) for the molecular diagnosis of endometrial receptivity (Fertil Steril 2011, 2013). He has been awarded “Prize Jaime I 2011 in Medical Investigation” for his pioneering work in human endometrial receptivity disorders.
In an independent bibliometric analysis considering publications in Reproductive Biology between 2003 and 2005, Carlos Simon was identified as the 9th most productive author in the world (Gonzalez-Alcaide G et al., Fertil Steril 90:941-56,2008).
Since 2001, he has expanded his research into the field of stem cells, resulting in the derivation, characterization, and registration in the Spanish National Stem Cell Bank (BNLC) of ten human embryonic stem cell (hESC) lines. He derived the first two hESC in Spain (Fertil Steril 2005) and described a new system for freezing hESC in the absence of animal contaminants. He derived VAL-6M, the first line with a monogenic disorder (Myotonic Dystrophy Type I) in Spain. Also, he obtained the first two hESC lines without destroying the human embryo using blastomere biopsy and demonstrated the lack of genetic diversity in the most common used hESC in the world (Mosher JT et al. N Engl J Med 2010). Finally, he reported the identification and characterization of human endometrial stem cells (Cervelló et al., PLoS ONE. 2010, 2011, 2012).
As Principal Investigator, his work has been funded through 16 projects sponsored by the Spanish Government, 4 by the Valencian Government, including 2 PROMETEO (granted to prestigious scientists) and 16 projects by international organizations, American Universities and private companies.
Metrics: At ISI Web of Knowledge Prof. Carlos Simon is author of 348 publications in international peer-review journals, adding up to an accumulated impact factor of 1,541.47. His papers have received a total of 11,139 cites with an average of 32 cites/paper. His H-Index is 60 and he is editor of 15 books. He has been Director of 28 PhD Thesis all qualified with “Cum Laude”, including 4 PhD Awards of Excellence and 3 European PhD. As inventor, his research has originated 13 Patent Applications, leading to the creation of IGENOMIX a biotech company.
As inventor, his research has originated 13 Patent Applications, leading to the creation of IGENOMIX a biotech company.
David earned a major in Business Science and an MBA from ESADE Business School. He is specialized in International Finance, with over 15 years of experience in consumer goods industries and 8 years in the health care industry. He has developed most of his career internationally, both in Europe and in America, working in Switzerland, US, Mexico and Spain.
He is an executive with broad private and public company backgrounds in both emerging and Fortune 500 companies. During his career, he has hold different responsibilities in Marketing, Finance, Business Development and IT providing him a wide view of business. David has been in general management for the last 8 years. He speaks fluent Spanish, English and French.
Since 2011, he has been the CEO of IGENOMIX, one of the leading companies in providing professional services in advanced molecular diagnoses in the reproductive medicine field.
Chief Financial Officer
Francisco B. Valor is a senior executive with more than 15 years of experience as a CFO. He has worked in privately-owned multinationals and public-listed companies in the chemical and food manufacturing sectors, as well as the healthcare services industry. He holds a B.A. of Business Administration from the University of Alicante (Spain) and earned his Executive MBA at the IESE Business School. He has extensive experience and knowledge of international and corporate finance and has helped companies go global in MEA, the USA, South America and Asia.
Product Development Director
David Blesa is Doctor in Biological Sciences by the Department of Genetics at the University of Valencia in Spain. Currently Dr. Blesa is the Head of the Product Development Department at IGENOMIX.
From 2011 until 2013 he has been Head of Research & Development at the IVI Foundation and also Head of the Product Development Department at IGENOMIX S.L.
From 2006 to 2011 he was Researcher and Head of the Genomics Core Facility at the ‘Principe Felipe Research Centre’ (CIPF) in Valencia, Spain. Previously, since 2000, he worked in the field of cancer genetics first as Postdoctoral Fellow at the ‘Hospital Clínico Universitario’ in Valencia and at the ‘Spanish National Cancer Research Centre’ (CNIO) in Madrid and later as a Researcher at the CNIO within the Molecular Cytogenetics Group until 2006.
His main interest is centered in the field of genetics and genomics of human health and specifically in reproductive health. He has been principal researcher in projects financed by the Valencian and the Spanish Science and Innovation Governmental Office and is author in more than 25 research papers published in international journals and author in several book chapters.
Trained in science in the University of Valencia, Spain, Dr Carmen Rubio specialized in cytogenetic studies in human reproduction, partly in the University of Barcelona.
Becoming interested in chromosomal abnormalities in human embryos, she completed her PhD in 2004 in Valencia in the field of Reproductive Genetics. Post-doctoral research includes a sabbatical at the laboratory of Drs. Patricia Hunt and Terry Hassold at the School of Molecular Biosciences (Washington State University, USA) focussed in male and female meiosis and the mechanism underlying human aneuploidy. At present, she is the Head of the Preimplantation Genetic Diagnosis program for chromosomal disorders at IGENOMIX (Valencia, Spain).
She has published more than 100 papers in the main peer-reviewed specialist journals in the field, books chapters as well as numerous lectures at conferences worldwide. She is one of the most cited authors in the field, with more than 20 year professional experience. She is Professor of the Master in Biotechnology from the University of Valencia.
Carrier Screening Director
Julio Martín completed his undergraduate in Biology in 1995 at the University of Barcelona (UB). He obtained a Master’s degree in Biotechnology in 1997 (UB, and Polytechnic University of Catalonia).
In 1998 he held a predoctoral research fellowship in the Department of Ob./Gyn., School of Medicine (University of Valencia) joining the group of Professor Carlos Simon at IVI foundation.
In 2002 he specialized in molecular genetics for in vitro embryo diagnosis at the Centre for Medical Genetics (UZ-Vrije Universiteit Brussel) joining the group of Dr. Sermon and Dr. De Rycke, directed by Professor Inge Liebaers. He has been director of the Laboratory of Molecular Diagnosis, (Preimplantation Genetic Diagnosis Unit) in the University Institute IVI Valencia since 2003.
Currently working in IGENOMIX as a Head of the PGD and molecular diagnosis department. His main interest is in the field of genetics of single-gene disorders and applied molecular technology to in vitro embryo diagnosis and non-invasive prenatal diagnosis.
Ana Cervero received her Bachelor degree and her Ph.D. in Biochemistry at Valencia University (Spain). In her research for the Ph.D., Ana Cervero was focused in human endometrial receptivity. Ana Cervero has over 7 years of clinical laboratory experience, first at IVI-Valencia Clinic (Spain) at the Preimplantation Genetic Diagnostic Laboratory and then at IVIOMICS (Spain) as a lab manager at the monogenic PGD and Molecular Diagnosis Department. In her research, Ana Cervero has been published in scientific journals including JCEM, Endocrinology, Molecular Human Reproduction and Fertility and Sterility.
Lorena Rodrigo received her Bachelor’s degree in Biology and her Ph.D. in Reproductive Genetics at Valencia University, Spain.
Lorena Rodrigo has over 14 years of clinical and research laboratory experience, starting at IVI University Institute (Valencia, Spain) and actually at IGENOMIX (Valencia, Spain). Becoming interested in chromosomal studies in spermatozoa from infertile patients and their implications in the reproductive outcome, she completed her PhD in the field of Reproductive Genetics in 2013. At present, she is the Lab Manager of the Preimplantation Genetic Diagnosis program for chromosomal disorders at IGENOMIX (Valencia, Spain), involved in molecular and cytogenetic testing of sperm and embryos.
Lorena Rodrigo received the Accreditation in Human Genetics from the Spanish Association of Human Genetics (AEGH) in 2012. She has over 20 peer-reviewed publications in respected scientific journals. She has presented at many national and international conferences.